



**QUEEN'S  
UNIVERSITY  
BELFAST**

## **Post-diagnostic calcium channel blocker use and breast cancer mortality: a population-based cohort study**

Busby, J., Mills, K., Zhang, S-D., Liberante, F., & Cardwell, C. (2018). Post-diagnostic calcium channel blocker use and breast cancer mortality: a population-based cohort study: a population-based cohort study. *Epidemiology*. <https://doi.org/10.1097/EDE.0000000000000814>

**Published in:**  
Epidemiology

**Document Version:**  
Peer reviewed version

**Queen's University Belfast - Research Portal:**  
[Link to publication record in Queen's University Belfast Research Portal](#)

### **Publisher rights**

© 2017 Lippincott, Williams & Wilkins.

This work is made available online in accordance with the publisher's policies. Please refer to any applicable terms of use of the publisher.

### **General rights**

Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

### **Take down policy**

The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact [openaccess@qub.ac.uk](mailto:openaccess@qub.ac.uk).

**Article Type:** Original Article

**Title:** Post-diagnostic calcium channel blocker use and breast cancer mortality: a population-based cohort study

**Authors:** John Busby<sup>1</sup>, Ken Mills<sup>2</sup>, Shu-Dong Zhang<sup>2</sup>, Fabio Giuseppe Liberante<sup>2</sup>, Chris Cardwell<sup>1</sup>

<sup>1</sup>Centre for Public Health, Queen's University Belfast, Belfast, UK

<sup>2</sup>Centre for Cancer Research and Cell Biology (CCRCB), Queen's University Belfast, Belfast, UK

**Correspondence:** Dr. John Busby, Centre for Public Health, Queen's University Belfast, Institute for Clinical Science, Royal Victoria Hospital, Grosvenor Road, Belfast, BT12 6BJ, +442890971640, john.busby@qub.ac.uk

## Abstract

**Background:** There have long been concerns that calcium channel blockers (CCBs), widely used to treat hypertension, may contribute to malignant growth through the evasion of apoptosis and proliferation of cancer cells. Worryingly, a recent cohort study found breast cancer patients who used CCBs had higher death rates, however interpreting these results was difficult as they were based on all-cause mortality and medication use before cancer diagnosis. Therefore, we used UK population-based data to more robustly investigate the association between CCB use and cancer-specific mortality.

**Patients and methods:** We selected a cohort of patients with newly-diagnosed breast cancer between 1998 and 2012 from English cancer registries. We linked to prescription and clinical records from the Clinical Practice Research Datalink, and to death records from the Office for National Statistics. We used time-dependent Cox-regression models to calculate hazard ratios (HRs) comparing breast cancer-specific and all-cause mortality between post-diagnostic CCBs users and non-users, after adjusting for demographics, comorbidities and other medication use.

**Results:** Our cohort included 23,669 breast cancer patients, of which 5,141 used CCBs and 3,053 died due to their breast cancer during follow-up. After adjustment, CCB users had similar breast cancer-specific mortality to non-users (HR=0.98, 95% CI: 0.88, 1.08). There was no evidence of a dose-response relationship. We found similar associations for specific CCBs, and for all-cause mortality.

**Conclusions:** In this large population-based breast cancer cohort, we did not find any evidence that CCB use is associated with increased mortality. Our findings should reassure GPs that CCBs are safe to prescribe to breast cancer patients.

**Keywords:** breast cancer, calcium channel blockers, pharmacology, epidemiology

**Key message:** Although experimental evidence suggests that calcium channel blockers might contribute to malignant growth, our population-based study of 23,669 breast cancer patient did not find any association between medication use and breast cancer mortality. This could suggest that previous findings of increased deaths among users where partly driven by confounding by indication and other biases.

## Introduction

Breast cancer is the second most common cancer in the world, with 1.7 million new cases diagnosed annually.[1, 2] Around 15% of patients die due to the disease within five years,[3] and they suffer markedly reduced quality of life, and substantially higher healthcare costs during treatment and recovery.[4-7]

Calcium channel blockers (CCBs) are a group of anti-hypertensive medications used to treat cardiovascular diseases such as hypertension and angina. In England, CCBs are recommended as the first-line treatment for hypertension, with around 40 million prescriptions dispensed annually.[8, 9] CCBs are also commonly used in the USA, with 6.5% of adults reporting using them within the last 30 days.[10] Despite their widespread use, there have long been concerns that CCBs may contribute to malignant growth through the evasion of apoptosis and proliferation of cancer cells.[11-13] In vitro and animal models have shown that CCBs reduce intracellular resting calcium concentration and inhibit apoptotic gene expression.[14, 15]

In humans, several studies have investigated the association between CCB use and breast cancer risk.[16] Although they have reached inconsistent conclusions, a recent meta-analysis concluded that long-term CCB use is associated with a statistically significant increase of 71% in breast cancer risk when compared to non-users.[16] The impact of CCB use on breast cancer progression has received much less attention. One study found a 22% increase in mortality among breast cancer patients who used CCBs when compared to non-users[17], however these findings are difficult to interpret because it did not identify cancer-specific deaths, adjust for comorbidities, test for a dose-response relationship, or assess CCB use after diagnosis. Consequently, we used population-based data from the UK to more robustly assess the association between CCB use and mortality among breast cancer patients.

## Methods

### Data Sources

Our study used data from the UK Clinical Practice Research Datalink (CPRD), linked to deprivation indices from census information, English cancer registry data from the National Cancer Data Repository (NCDR), and death registration data from the Office for National Statistics (ONS). The CPRD contains computerised medical records from 674 general practices (approximately 7% of the UK population) which are audited for data completeness and quality.[18] Practices meeting a predefined quality standard are deemed 'up to standard' and included in future extracts. Data recorded includes patient demographics, clinical diagnoses (using Read codes) and prescription medication use. Previous research has found CPRD prescription and clinical information to be of high quality.[18-20] The NCDR holds UK-wide data from English cancer registries compiled from a variety of sources including general practices, cancer screening programmes, NHS and private hospitals, and death certificates.[21] ONS death-registration data provide details on the date and cause(s) of death.

### Study Design and Population

We used the NCDR to identify a cohort of female patients with newly-diagnosed breast cancer (ICD code C50) between 1998 and 2012. Cohort members with a previous record of cancer were identified and excluded from the analysis using a list of cancer Read codes modified for use in the CPRD.[22] Patients were excluded if they were diagnosed before they were registered with a CPRD practice, before their practice was deemed up to research standard, after they left a CPRD practice, or after data was last collected from their practice by the CPRD. A small number of patients were recorded within the NCDR more than once, when this occurred we used their first record. Patients with stage 0 breast cancer (ductal carcinoma in situ) were also excluded.

Deaths were identified from ONS records, and breast cancer specific deaths were defined as those with a primary cause of breast cancer (ICD code C50). Patients who died within the first year of the study were excluded as it is unlikely that these could be influenced by post-diagnostic medication use, therefore the follow-up period started from 1-year after diagnosis. The end of follow-up was the earliest date of death, end of registration with the practice, last collection of data from the practice, or last linkage between the CPRD and ONS death records.

### Definition of exposure

We used the British National Formulary to compile a list proprietary and generic medication names for CCBs (Appendix 1). We added a lag of 12 months to CCB use as these medications are unlikely to have an immediate effect on breast cancer progression, and to prevent reverse causation.[23, 24] A diagram illustrating our design is shown in Appendix 2. We defined patients as users if they had at least one CCB prescription during the exposure period. Our medication data did not include details on whether the medication was dispensed, or eventually used by the patient. To enable the testing of dose-response relationships we extracted data on the medication prescribed, number of packs / tablets and medication strength, and calculated defined daily doses (DDDs). The DDD system is a validated measure of drug consumption maintained by the World Health Organisation.[25] A single DDD is the average maintenance dose per day of a drug used for its main indication in adults (e.g. hypertension for CCBs). There was insufficient information to calculate DDDs for 0.2% of prescriptions, and implausible values were recorded in a further 0.1% (e.g. 1 tablet; >50,000 tablets). In these cases we assumed the most common DDD based on other prescriptions with complete information. We calculated a running DDD total for each patient and identified the day when patients received their 1<sup>st</sup> (first use), 365<sup>th</sup> (one year's use), 1095<sup>th</sup> (three year's use) and 1825<sup>th</sup> (five year's use) DDD.

## Covariates

Patients' age, smoking, alcohol, and obesity (BMI>30) data were determined from the closest GP record before breast cancer diagnosis (values more than 10 years before diagnoses were ignored). We used GP records to identify pre-diagnosis comorbidities (cerebrovascular disease, chronic pulmonary disease, congestive heart disease, diabetes, liver disease, myocardial infarction, peptic ulcer disease, peripheral vascular disease, renal disease), using a list of Read codes modified for use in the CPRD[22], as comorbidities have been consistently associated with higher cancer mortality.[26]

Deprivation data was available from census information, and based on the 2010 Index of Multiple Deprivation (IMD) score of the patient's postcode. The NCDR included detailed information about the patient's cancer, including diagnosis year, stage, histologic grade, and treatment (surgery, chemotherapy, and radiotherapy). We used CPRD prescription records to identify patients who received hormone therapy treatment (tamoxifen or aromatase inhibitors), and those who had used oral contraceptives or hormone replacement therapy (HRT) prior to diagnosis, as these have been shown to influence breast cancer progression previously.[27, 28]

## Statistical analysis

We calculated descriptive statistics and compared the demographic and clinical characteristics of the CCB users and non-users, and calculated 1-, 2- and 5-year cancer specific survival probabilities. We used time-dependent Cox regression models to calculate hazard ratios (HRs) comparing breast cancer-specific death between CCB users and non-users. In our primary analysis we included CCB use as a time-varying covariate to avoid immortal time bias.[29] Therefore patients were initially included within the analysis as non-users until 12 months after their first use (due to the exposure lag), after which they were included as users. Our primary analysis adjusted for age at diagnosis, year of diagnosis, deprivation quintile, comorbidities (separate terms for each), prior use of HRT or oral

contraceptives, and treatment within six months of diagnosis (separate terms for surgery, chemotherapy, radiotherapy, tamoxifen, aromatase inhibitors). Comorbidities were not included as time-varying covariates due to the possibility that changes in health status could lie on the causal pathway between CCB use and breast cancer mortality. We repeated our analysis by number of DDDs prescribed (e.g. patients were included in the 1-364 DDD group until 12<sup>th</sup> months after they received their 365<sup>th</sup> DDD), and for each commonly prescribed CCB medication ( $\geq 2\%$  usage in cohort).

### Sensitivity and subgroup analyses

We conducted sensitivity analysis for all-cause mortality, and for cause-specific mortality where the definition of breast cancer death was expanded to include secondary causes of death. We also conducted sensitivity analysis with a lag period of zero (patients followed-up from diagnosis), six months (patients followed-up from six months after diagnosis) and two years (patients followed-up from two years after diagnosis). We performed two simplified analyses which controlled for immortal time bias without requiring time-varying covariates.[29] Firstly, we based CCB usage on the year after diagnosis, and restricted our analysis to patients living at least one year. Secondly, we based CCB usage on the year prior to diagnosis, and followed-up patients from the date of diagnosis. Diagrams illustrating the design of our sensitivity analyses which vary the exposure lag and/or period are given in Appendix 2. To facilitate comparison between studies we repeated our analysis using methods broadly similar to the previous *Holmes et al* analysis for all-cause, breast cancer and cardiovascular (ICD 10 codes: I0-I99, G45, Q20-26, F01) deaths. Specifically, we based CCB usage on the year prior to breast cancer diagnosis, did not adjust for comorbidities, and restricted the non-user group to those who did not receive any anti-hypertensive medication (diuretics, vasodilator antihypertensive drugs, centrally acting antihypertensive drugs, alpha-adrenoceptor blocking drugs, beta-blockers, ACEIs, ARBs, renin inhibitors, and calcium channel blockers) during the exposure period.

To ensure that confounding by indication was not driving our results we conducted three further sensitivity analysis restricted to patients with similar diagnoses. First, we restricted our analysis to patients with a record of hypertension (Read code categories G20 and 662) in the year prior to diagnosis. Second, we restricted our analysis to patients who used an anti-hypertensive medication in the year prior to breast cancer diagnosis. Third, we compared patients who received CCBs to those who received a different anti-hypertensive medication after diagnosis (using a time-varying covariate) as the use of an active comparison can overcome several common pharmacoepidemiological biases.[30]

We performed additional sensitivity analysis adjusting for cancer diagnosis details (stage, grade) and patient lifestyle (smoking, alcohol consumption, obesity) using complete-case and multiple imputation with chained equations (MICE). The MICE imputation used ordered logit models with age, deprivation, death indicator and the baseline hazard function as covariates.[31] Briefly, MICE is a simulation-based approach for handling missing data which leads to valid statistical inferences under certain circumstances.[32] Finally, we conducted a complete case analysis adjusting for cancer diagnosis details (stage, grade), but limited to patients registered with the Northern & Yorkshire Cancer Registry, the registry with the most complete staging information in England (92% of all patients). Restricting our analysis to patients with more complete data could help reduce potential biases due to missing confounder data. Lastly, we used the Fine and Gray sub-distribution hazard model to assess the impact of competing risks from non-breast cancer deaths.[33]

## Results

### Cohort Description

There were 54,190 breast cancer cases recorded within the NCDR between 1998 and 2012. We excluded 30,521 patients from the analysis, most commonly because they were diagnosed before they registered with a CPRD practice or before their practice was deemed up to research standard (n=12,418), they were diagnosed after they left a CPRD practice or data was last collected from it (n=9,989), they had a record of previous cancer (n=4,775), or they lived for less than 12 months after diagnosis (n=3,189). Therefore, our analysis cohort included 23,669 patients (126,154 person-years), of which 5,141 (21.7%) were CCB users (21,834 person-years). Median follow-up was 5.5 years (maximum 17.8 years). CCB users were more likely to be older, from a deprived area, have comorbidities, be treated with aromatase inhibitors, have lower stage cancer, be non- or ex-smokers, consume no alcohol, and be obese (Table 1).

### Association between CCB use and mortality

Overall, CCB users were at a higher risk of breast cancer death than non-users (unadjusted HR=1.13, 95% CI: 1.03, 1.25; Table 2). Consequently, cancer-specific survival was slightly lower among CCB users at 1- (0.96 vs. 0.97), 2- (0.93 vs. 0.94) and 5-years (0.86 vs. 0.88) from start of follow-up. However, after adjustment for demographics, comorbidities, treatment and other medication use, CCB users had a similar risk of breast cancer death (adjusted HR=0.98, 95% CI: 0.88, 1.08). There was no evidence of a dose-response relationship; we observed small differences in breast cancer death even when comparing non-users to those who received at least 1,825 DDDs (adjusted HR=0.97, 95% CI=0.76, 1.24). Similarly, there was no evidence of an association between medication use and breast cancer death for any of the four specific CCBs included in our analysis, with adjusted HRs ranging from 0.95 (95% CI: 0.77, 1.19) for felodipine to 1.05 (95% CI: 0.93, 1.19) for amlodipine (Table 2).

## Sensitivity and subgroup analyses

Our results were similar in the simpler analysis basing CCB use on the first year after diagnosis (Table 3). Classifying CCB using the year prior to diagnosis lead to a slightly higher association (adjusted HR=1.06, 95% CI: 0.95, 1.19), although this was broadly consistent with our main analysis. CCB users had a much higher risk of all-cause death (unadjusted HR: 1.59, 95% CI: 1.49, 1.69), however this was substantially attenuated to 1.04 (95% CI: 0.97, 1.11) after adjustment. Our results were robust to changes in the exposure lag period from zero to two years, when expanding our breast cancer-specific death definition to include secondary causes, when accounting for competing causes of death, and did not change appreciably when adjusting for cancer diagnosis (i.e. stage, grade) or patient lifestyle factors using complete case or multiple imputation methods. We observed broadly similar hazard ratios when restricting our analysis to patients with a prior diagnosis of hypertension (0.89; 95% CI: 0.71, 1.12), to those in receipt of anti-hypertensive medications before diagnosis (0.95; 95% CI: 0.84, 1.07), or when comparing CCB users to patients receiving a different anti-hypertensive medication after breast cancer diagnosis (1.02; 95% CI: 0.92, 1.13). When repeating the analysis using similar methods to *Holmes et al*, we found substantially higher all-cause mortality among CCB users (HR=1.27; 95% CI: 1.17, 1.38), but this largely reflected cardiovascular (HR=2.22; 95% CI: 1.81, 2.72) rather than breast cancer (HR=1.11; 95% CI: 0.98, 1.25) deaths.

## Discussion

### Summary of main findings

In this large, population-based cohort of newly-diagnosed breast cancer patients, we did not observe any evidence of an increase in breast cancer-specific mortality with CCB use after adjustment for patient demographics, comorbidities and other medication use. There was no evidence of a dose-response relationship. We found similar associations for specific CCBs and for all-cause mortality.

### Strengths and weaknesses

Our study is the first to investigate post-diagnosis CCB use and breast cancer-specific mortality. It is based on a high-quality population-based cohort of patients with registry-confirmed breast cancer[18], and is more than five-times larger than previous work.[17] Patients included in the study had a long follow-up period after diagnosis of up to 17 years, which should allow any clinically important effect of CCBs on breast cancer progression to become apparent. Linkage to ONS death registration data allowed robust verification of death, and facilitated a breast cancer-specific analysis, which should be more sensitive to small-changes in disease-specific mortality, and less susceptible to confounding by indication than all-cause deaths.[24, 34] Although some misclassification of death cause is possible, studies have shown this is likely to have a limited impact on our estimates (as there is no obvious mechanism for differential misclassification)[35] and our results were similar when expanding our breast-cancer death definition to include secondary causes.

We used prescribing data collected as part of routine clinical care which accurately reflects GP prescribing practices and negates the risk of recall bias. This data also included detailed information on the type of CCB, and the strength, quantity and timing of prescription, which allowed us to investigate dose-response relationships, and conduct separate analysis for specific medications.

CCBs are not available over-the-counter in the UK, which negates exposure misclassification due to over-the-counter usage.

Our study has several potential weaknesses. It is observational and hence open to confounding. Although we have adjusted for several of the key determinants of breast cancer progression (e.g. age, comorbidities and treatment), some risk factors, including ethnicity and nutrition, were not available within our dataset.[36, 37] Other important prognostic variables such as cancer stage and grade were incomplete, and so omitted from our primary analysis. The reason stage was not available for a high proportion of breast cancer patients within the NCDR is unclear, however similar patterns have been reported elsewhere.[38] Nevertheless, the findings from our sensitivity analyses suggest that confounding or missing data issues were not solely driving our results. For example, our conclusions were unchanged when using multiple imputation to adjust for cancer stage and grade, or restricting our analysis to a single registry with almost complete staging data. Moreover, we observed little evidence of an association when using other antihypertensive medications as an active comparator (which should be confounded in a similar way to CCBs). The proportion of patients receiving surgery is slightly lower than reported in note reviews from Northern Ireland (which has a similar healthcare system to England)[41], suggesting that some misclassification of cancer treatment is possible.

Lastly, we do not know if patients adhered to their prescribed medications, however our main conclusions were similar when restricting our analysis to patients who received multiple prescriptions (>1,825 DDDs), where non-compliance is less of a concern.

### [Comparison with previous work](#)

We are unaware of any other studies which have compared breast-cancer specific mortality between CCB users and non-users. One recent cohort study of 4,019 Canadian patients with registry-

confirmed breast cancer by *Holmes et al* reported a 22% (HR= 1.22; 95% CI: 1.02, 1.47) increase in all-cause mortality among CCB users.[17] However, this study did not examine post-diagnostic medication use, did not investigate cancer-specific mortality, could not adjust for comorbidities, restricted their non-user group to patients not receiving anti-hypertensive medications, and had much shorter follow-up (maximum of 6 years) than our study. We found a comparable increase of 27% (HR= 1.27; 95% CI: 1.17, 1.38) in our cohort when using similar methods to those employed by *Holmes et al*, which was largely driven by cardiovascular deaths (HR= 2.22; 95% CI: 1.81, 2.72), suggesting that their estimates may have been substantially inflated by these potential weaknesses.

### Implications for practice

CCBs are a widely used and effective treatment for cardiovascular conditions such as hypertension and angina. Although concerns have persisted that their use may lead to malignant growth through increased apoptotic evasion and cancer cell proliferation[11-13], our study suggests that this does not manifest in increased breast-cancer mortality. Consequently, general practitioners and patients with breast cancer should not be unduly concerned when prescribing or taking these medications.

### Conclusions

In this large population-based cohort of patients with registry-confirmed breast-cancer, we did not find any evidence that CCB use is associated with increased mortality. Our findings should reassure GPs that they are safe to prescribe these medications to this patient group.

### Disclosures

**Funding:** This work was supported by a project grant from Cancer Research-UK [C37316/A18225]

**Conflict of Interest:** The authors have declared no conflicts of interest

**Acknowledgements:** This study is based in part on data from the Clinical Practice Research Datalink obtained under licence from the UK Medicines and Healthcare products Regulatory Agency. However, the interpretation and conclusions contained in this study are those of the author/s alone. This study protocol (16\_079R) was reviewed and approved by the ISAC committee.

## References

1. Office for National Statistics. Cancer Registration Statistics 2014, England. In. 2016.
2. GLOBOCAN. Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. In. 2012.
3. Office for National Statistics. Cancer survival in England: Patients diagnosed between 2010 and 2014 and followed up to 2015. In. 2016.
4. Blair CK, Robien K, Inoue-Choi M et al. Physical inactivity and risk of poor quality of life among elderly cancer survivors compared to women without cancer: the Iowa Women's Health Study. *Journal of Cancer Survivorship* 2016; 10: 103-112.
5. Klein D, Mercier M, Abeilard E et al. Long-term quality of life after breast cancer: a French registry-based controlled study. *Breast Cancer Research and Treatment* 2011; 129: 125-134.
6. Keetharuth A, Dixon S, Winter M et al. Effects Of Cancer Treatment On Quality Of Life (ECTQOL): Final Results. In. Sheffield: Decision Support Unit, SchARR 2014.
7. Luengo-Fernandez R, Leal J, Gray A, Sullivan R. Economic burden of cancer across the European Union: a population-based cost analysis. *The Lancet Oncology* 2013; 14: 1165-1174.
8. McManus RJ, Caulfield M, Williams B. NICE hypertension guideline 2011: evidence based evolution. *Bmj* 2012; 344: e181.
9. Powell-Smith A, Goldacre B. OpenPrescribing.net. In. 2016.
10. Kantor ED, Rehm CD, Haas JS et al. Trends in Prescription Drug Use Among Adults in the United States From 1999-2012. *Jama* 2015; 314: 1818-1831.
11. Hanahan D, Weinberg RA. The hallmarks of cancer. *Cell* 2000; 100: 57-70.
12. Pahor M, Guralnik JM, Salive ME et al. Do calcium channel blockers increase the risk of cancer? *American Journal of Hypertension* 1996; 9: 695-699.
13. Mason RP. Calcium channel blockers, apoptosis and cancer: Is there a biologic relationship? *Journal of the American College of Cardiology* 1999; 34: 1857-1866.
14. Jang SJ, Choi HW, Choi DL et al. In vitro cytotoxicity on human ovarian cancer cells by T-type calcium channel blockers. *Bioorganic & Medicinal Chemistry Letters* 2013; 23: 6656-6662.
15. Altamirano F, Valladares D, Henriquez-Olguin C et al. Nifedipine treatment reduces resting calcium concentration, oxidative and apoptotic gene expression, and improves muscle function in dystrophic mdx mice. *PLoS One* 2013; 8: e81222.
16. Li W, Shi Q, Wang WB et al. Calcium Channel Blockers and Risk of Breast Cancer: A Meta-Analysis of 17 Observational Studies. *Plos One* 2014; 9.
17. Holmes S, Griffith EJ, Musto G, Minuk GY. Antihypertensive medications and survival in patients with cancer: a population-based retrospective cohort study. *Cancer Epidemiol* 2013; 37: 881-885.
18. Herrett E, Gallagher AM, Bhaskaran K et al. Data Resource Profile: Clinical Practice Research Datalink (CPRD). *Int J Epidemiol* 2015; 44: 827-836.
19. Herrett E, Thomas SL, Schoonen WM et al. Validation and validity of diagnoses in the General Practice Research Database: a systematic review. *Br J Clin Pharmacol* 2010; 69: 4-14.
20. Jick H, Jick SS, Derby LE. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. *Bmj* 1991; 302: 766-768.
21. National Cancer Intelligence Network. National Cancer Data Repository. In. 2016.
22. Khan NF, Perera R, Harper S, Rose PW. Adaptation and validation of the Charlson Index for Read/OXMIS coded databases. *BMC Fam Pract* 2010; 11: 1.
23. Tamim H, Monfared AA, LeLorier J. Application of lag-time into exposure definitions to control for protopathic bias. *Pharmacoepidemiol Drug Saf* 2007; 16: 250-258.
24. Chubak J, Boudreau DM, Wirtz HS et al. Threats to validity of nonrandomized studies of postdiagnosis exposures on cancer recurrence and survival. *J Natl Cancer Inst* 2013; 105: 1456-1462.
25. World Health Organization. The Anatomical Therapeutic Chemical Classification System With Defined Daily Doses. In. 2016.

26. Sarfati D, Koczwara B, Jackson C. The impact of comorbidity on cancer and its treatment. *CA: A Cancer Journal for Clinicians* 2016; 66: 337-350.
27. Gierisch JM, Coeytaux RR, Urrutia RP et al. Oral Contraceptive Use and Risk of Breast, Cervical, Colorectal, and Endometrial Cancers: A Systematic Review. *Cancer Epidemiology Biomarkers & Prevention* 2013; 22: 1931-1943.
28. Nelson HD, Humphrey LL, Nygren P et al. Postmenopausal hormone replacement therapy - Scientific review. *Jama-Journal of the American Medical Association* 2002; 288: 872-881.
29. Lévesque LE, Hanley JA, Kezouh A, Suissa S. Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. *BMJ* 2010; 340.
30. Lund JL, Richardson DB, Stürmer T. The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application. *Current epidemiology reports* 2015; 2: 221-228.
31. White IR, Royston P. Imputing missing covariate values for the Cox model. *Statistics in Medicine* 2009; 28: 1982-1998.
32. White IR, Royston P, Wood AM. Multiple imputation using chained equations: Issues and guidance for practice. *Stat Med* 2011; 30: 377-399.
33. Fine JP, Gray RJ. A Proportional Hazards Model for the Subdistribution of a Competing Risk. *Journal of the American Statistical Association* 1999; 94: 496-509.
34. Steele RJC, Brewster DH. Should we use total mortality rather than cancer specific mortality to judge cancer screening programmes? No. *BMJ* 2011; 343.
35. Sarfati D, Blakely T, Pearce N. Measuring cancer survival in populations: relative survival vs cancer-specific survival. *Int J Epidemiol* 2010; 39: 598-610.
36. Li CI, Malone KE, Daling JR. Differences in breast cancer stage, treatment, and survival by race and ethnicity. *Archives of Internal Medicine* 2003; 163: 49-56.
37. Chlebowski RT, Blackburn GL, Thomson CA et al. Dietary fat reduction and breast cancer outcome: Interim efficacy results from the Women's Intervention Nutrition Study. *Journal of the National Cancer Institute* 2006; 98: 1767-1776.
38. Walters S, Maringe C, Butler J et al. Breast cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK, 2000-2007: a population-based study. *Br J Cancer* 2013; 108: 1195-1208.
39. Bastiaannet E, Liefers GJ, de Craen AJ et al. Breast cancer in elderly compared to younger patients in the Netherlands: stage at diagnosis, treatment and survival in 127,805 unselected patients. *Breast Cancer Res Treat* 2010; 124: 801-807.
40. Rutherford MJ, Hinchliffe SR, Abel GA et al. How much of the deprivation gap in cancer survival can be explained by variation in stage at diagnosis: an example from breast cancer in the East of England. *Int J Cancer* 2013; 133: 2192-2200.
41. Cairnduff V, Fitzpatrick D, Gavin A. Monitoring care of female breast cancer patients in Northern Ireland diagnosed 2012 (with comparisons to 1996, 2001 & 2006). In. Belfast: N. Ireland Cancer Registry 2015.

## Tables and Figures

**Table 1: Patient characteristics by CCB use at any time after diagnosis, restricted to patients living more than 1 year after diagnosis.**

	All Patients	CCB Use	
		Non-user	User
<b>Number of Patients</b>	23,669	18,528	5,141
<b>Person Years</b>	126,154	104,320	21,834
<b>Year of Diagnosis</b>			
1998-2002	5,738 (24.2%)	4,316 (23.3%)	1,422 (27.7%)
2003-2007	8,776 (37.1%)	6,756 (36.5%)	2,020 (39.3%)
2008-2012	9,155 (38.7%)	7,456 (40.2%)	1,699 (33.0%)
<b>Age at Diagnosis (SD)</b>	61.9 (14.0)	59.9 (14.1)	68.8 (11.3)
0-49	4,774 (20.2%)	4,550 (24.6%)	224 (4.4%)
50-59	5,913 (25.0%)	5,041 (27.2%)	872 (17.0%)
60-69	5,955 (25.2%)	4,360 (23.5%)	1,595 (31.0%)
70-79	4,037 (17.1%)	2,577 (13.9%)	1,460 (28.4%)
80+	2,990 (12.6%)	2,000 (10.8%)	990 (19.3%)
<b>Deprivation Quintile</b>			
1 (Least Deprived)	6,026 (25.5%)	4,901 (26.5%)	1,125 (21.9%)
2	6,087 (25.7%)	4,717 (25.5%)	1,370 (26.7%)
3	4,873 (20.6%)	3,846 (20.8%)	1,027 (20.0%)
4	3,941 (16.7%)	3,013 (16.3%)	928 (18.1%)
5 (Most Deprived)	2,733 (11.6%)	2,043 (11.0%)	690 (13.4%)
Missing	9	8	1
<b>Comorbidities</b>			
Chronic Pulmonary Disease	2,716 (11.5%)	1,985 (10.7%)	731 (14.2%)
Diabetes	1,456 (6.2%)	839 (4.5%)	617 (12.0%)
Renal Disease	1,076 (4.5%)	646 (3.5%)	430 (8.4%)
Cerebrovascular Disease	650 (2.7%)	406 (2.2%)	244 (4.7%)
Congestive Heart Disease	345 (1.5%)	241 (1.3%)	104 (2.0%)
Peripheral Vascular Disease	264 (1.1%)	134 (0.7%)	130 (2.5%)
Myocardial Infarction	250 (1.1%)	160 (0.9%)	90 (1.8%)
Peptic Ulcer Disease	238 (1.0%)	162 (0.9%)	76 (1.5%)
Liver Disease	45 (0.2%)	33 (0.2%)	12 (0.2%)
<b>Confounder Medications</b>			
Hormone Replacement Therapy	7,002 (29.6%)	5,693 (30.7%)	1,309 (25.5%)
Oral Contraceptive	6,009 (25.4%)	5,132 (27.7%)	877 (17.1%)
<b>Prior CCB Use</b>	2,802 (11.8%)	309 (1.7%)	2,493 (48.5%)
<b>Treatment</b>			
Surgery	19,218 (81.2%)	15,040 (81.2%)	4,178 (81.3%)
Tamoxifen	14,445 (61.0%)	11,358 (61.3%)	3,087 (60.0%)
Aromatase inhibitors	11,914 (50.3%)	8,996 (48.6%)	2,918 (56.8%)
Radiotherapy	8,320 (35.2%)	6,298 (34.0%)	2,022 (39.3%)
Chemotherapy	6,774 (28.6%)	5,968 (32.2%)	806 (15.7%)
<b>Grade</b>			
1	3,780 (17.9%)	2,846 (17.3%)	934 (20.1%)
2	10,282 (48.7%)	7,926 (48.1%)	2,356 (50.8%)
3	7,039 (33.3%)	5,698 (34.6%)	1,341 (28.9%)
4	19 (0.1%)	14 (0.1%)	5 (0.1%)
Missing	2,549	2,044	505
<b>Stage</b>			
1	4,791 (49.0%)	3,748 (48.3%)	1,043 (51.5%)
2	3,936 (40.2%)	3,135 (40.4%)	801 (39.6%)
3	748 (7.6%)	611 (7.9%)	137 (6.8%)

4	309 (3.2%)	265 (3.4%)	44 (2.2%)
Missing	13,885	10,769	3,116
<b>Smoking</b>			
No	12,980 (61.3%)	10,126 (61.3%)	2,857 (61.3%)
Ex	4,675 (22.1%)	3,516 (21.3%)	1,153 (24.7%)
Yes	3,523 (16.6%)	2,876 (17.4%)	650 (13.9%)
Missing	2,491	2,010	481
<b>Alcohol</b>			
No	3,406 (19.7%)	2,449 (18.3%)	960 (24.3%)
Ex	350 (2.0%)	245 (1.8%)	103 (2.6%)
Yes	13,574 (78.3%)	10,678 (79.9%)	2,895 (73.1%)
Missing	6,339	5,156	1,183
<b>Obesity</b>			
Normal	7,724 (41.0%)	6,389 (44.0%)	1,333 (31.0%)
Overweight	6,324 (33.6%)	4,768 (32.8%)	1,559 (36.2%)
Obese	4,777 (25.4%)	3,366 (23.2%)	1,410 (32.8%)
Missing	4,844	4,005	839

---

**Table 2: Association between CCB use and breast cancer mortality**

	<b>N</b>	<b>Person-Years</b>	<b>Deaths</b>	<b>Unadjusted HR</b>	<b>Age-adjusted HR</b>	<b>Fully-adjusted HR<sup>a</sup></b>
<b>Calcium-channel blockers</b>						
Never	18,528	104,320	2,522	Ref	Ref	Ref
Ever	5,141	21,834	531	1.13 (1.03,1.25)	0.93 (0.84,1.02)	0.98 (0.88,1.08)
1-364 DDDs	1,679	8,275	224	1.14 (0.99,1.31)	0.94 (0.82,1.08)	0.98 (0.85,1.13)
365-1094 DDDs	1,340	6,268	155	1.07 (0.91,1.26)	0.87 (0.73,1.02)	0.91 (0.77,1.08)
1095-1824 DDDs	841	3,237	82	1.31 (1.05,1.64)	1.07 (0.85,1.33)	1.13 (0.90,1.41)
1825+	1,281	4,054	70	1.10 (0.86,1.40)	0.90 (0.71,1.15)	0.97 (0.76,1.24)
<b>Amlodipine</b>						
Never	20,404	113,604	2,747	Ref	Ref	Ref
Ever	3,265	12,550	306	1.16 (1.03,1.30)	0.98 (0.87,1.10)	1.05 (0.93,1.19)
<b>Felodipine</b>						
Never	22,799	122,284	2,969	Ref	Ref	Ref
Ever	870	3,870	84	1.05 (0.84,1.30)	0.88 (0.71,1.10)	0.95 (0.77,1.19)
<b>Nifedipine</b>						
Never	23,035	122,954	2,966	Ref	Ref	Ref
Ever	634	3,200	87	1.24 (1.00,1.54)	1.04 (0.84,1.29)	0.97 (0.78,1.20)
<b>Diltiazem</b>						
Never	23,107	123,731	2,988	Ref	Ref	Ref
Ever	562	2,423	65	1.24 (0.97,1.59)	1.05 (0.82,1.34)	1.05 (0.82,1.34)

<sup>a</sup> Adjusted for age, deprivation, year of diagnosis, cancer treatment within 6 months (radiotherapy, chemotherapy, surgery, tamoxifen, aromatase inhibitors), comorbidities (cerebrovascular disease, chronic pulmonary disease, congestive heart disease, diabetes, liver disease, myocardial infarction, peptic ulcer disease, peripheral vascular disease, renal disease) and other medication use (prior use of hormone replacement therapy, oral contraceptives).

**Table 3: Sensitivity and subgroup analysis for CCB use and breast cancer mortality**

	Non-Users <sup>f</sup>			Users			Unadjusted HR	Fully-adjusted HR <sup>a</sup>
	N	PY	Deaths <sup>g</sup>	N	PY	Deaths		
<b>Main analysis</b>	18,528	104,320	2,522	5,141	21,834	531	1.13 (1.03,1.25)	0.98 (0.88,1.08)
<b>Death definition</b>								
All-cause	18,528	104,320	4,032	5,141	21,834	1,259	1.59 (1.49,1.69)	1.04 (0.97,1.11)
Primary or secondary breast cancer cause	18,528	104,320	2,881	5,141	21,834	677	1.27 (1.16,1.38)	0.99 (0.91,1.09)
<b>Exposure definition</b>								
Year before diagnosis	20,875	134,349	2,661	2,794	15,474	392	1.25 (1.13,1.39)	1.06 (0.95,1.19)
Year after diagnosis	20,627	112,089	2,645	3,042	14,066	408	1.17 (1.05,1.30)	1.00 (0.89,1.11)
<b>Exposure lag</b>								
None	18,033	122,578	2,453	5,636	27,245	600	1.12 (1.02,1.22)	0.96 (0.88,1.06)
6 months	18,132	118,071	2,464	5,416	24,471	575	1.14 (1.04,1.25)	0.98 (0.89,1.08)
2 years	18,253	113,486	2,478	4,365	17,090	370	1.10 (0.98,1.23)	0.97 (0.86,1.09)
<b>Hypertension diagnosis / treatment</b>								
Pre-diagnosis hypertension diagnosis	1,396	7,487	199	1,287	5,806	137	0.99 (0.80,1.24)	0.89 (0.71,1.12)
Pre-diagnosis anti-hypertensive medication users	4,879	24,907	764	3,718	16,136	434	0.99 (0.88,1.12)	0.95 (0.84,1.07)
CCB vs. other anti-hypertensive medication	3,426	15,562	405	5,141	21,834	531	1.02 (0.90,1.16)	0.99 (0.87,1.12)
<b>Holmes study methodology<sup>b</sup></b>								
All-cause deaths	15,080	100,242	2,710	2,794	15,474	883	2.14 (1.98,2.31)	1.27 (1.17,1.38)
Breast cancer deaths	15,080	100,242	1,856	2,794	15,474	392	1.34 (1.20,1.49)	1.11 (0.98,1.25)
Cardiovascular deaths	15,080	100,242	202	2,794	15,474	211	7.05 (5.80,8.56)	2.22 (1.81,2.72)
<b>Adjustment</b>								
CC lifestyle <sup>c</sup>	12,193	69,352	1,534	3,665	15,437	354	1.15 (1.03,1.29)	1.03 (0.91,1.17)
MI lifestyle	18,528	104,320	2,522	5,141	21,834	531	1.13 (1.03,1.25)	0.97 (0.88,1.07)
CC diagnosis <sup>d</sup>	7,327	40,504	808	1,924	7,895	169	1.18 (1.00,1.39)	1.06 (0.89,1.27)
CC diagnosis, most complete staging registry	1,312	7,102	178	330	1,420	34	1.06 (0.73,1.54)	1.03 (0.69,1.55)
MI diagnosis	18,528	104,320	2,522	5,141	21,834	531	1.13 (1.03,1.25)	0.97 (0.88,1.08)
<b>Competing risks regression</b>	18,528	104,320	2,522	5,141	21,834	531	1.10 (1.01,1.21)	1.05 (0.95,1.15)

<sup>a</sup> Adjusted for age, deprivation, year of diagnosis, cancer treatment within 6 months (radiotherapy, chemotherapy, surgery, tamoxifen, aromatase inhibitors), comorbidities (cerebrovascular disease, chronic pulmonary disease, congestive heart disease, diabetes, liver disease, myocardial infarction, peptic ulcer disease, peripheral vascular disease, renal disease) and other medication use (prior use of hormone replacement therapy, oral contraceptives).

<sup>b</sup> CCB usage based on the year prior to breast cancer diagnosis, no adjustment for comorbidities, and non-user group restricted to those who did not receive any anti-hypertensive medication during the exposure period

<sup>c</sup> Complete case, additionally adjusted for smoking, obesity and alcohol consumption

<sup>d</sup> Multiply imputed, additionally adjusted for stage and grade

<sup>e</sup> Multiply imputed, additionally adjusted for stage and grade. Restricted to patients included in the Northern & Yorkshire Cancer Registry, which has staging information for over 92% of patients

<sup>f</sup> Except for 'CCB vs. other anti-hypertensive medication' where patients who received a different anti-hypertensive medication serve as the reference group

<sup>g</sup> Deaths with a primary cause of breast cancer unless otherwise stated






<sup>h</sup> Using the Fine and Gray sub-distribution hazard model with non-breast cancer death as competing risk

## Appendices

### Appendix 1: List of generic and proprietary drug names used to identify calcium channel blocker use

<b>Substance</b>	<b>Medication</b>
Amlodipine	Amlodipine, Amlostin, Exforge, Istin
Diltiazem	Diltiazem, Adizem, Angitil, Dilcardia, Dilzem, Slozem, Tildiem, Viazem, Zemtard
Felodipine	Felodipine, Cardioplen, Felogen, Felotens, Keloc, Neofel, Parmid, Plendil, Triapin, Vascalpha
Isradipine	Isradipine
Lacidipine	Lacidipine, Motens
Lercanidipine	Lercanidipine, Zanidip
Nicardipine	Nicardipine, Cardene
Nifedipine	Nifedipine, Adalat, Adipine, Beta-Adalat, Calchan, Coracten, Fortipine, Kentipine, Nifedipress, Tenif, Tensipine, Valni
Nimodipine	Nimodipine, Nimotop
Verapamil	Verapamil, Cordilox, Securon, Univer, Verapress, Vertab, Zolvera

**Appendix 2: Illustration of study design for selected analyses<sup>a</sup>**



**Legend:** Before FUP CCB User CCB Non-user

<sup>a</sup> FUP: follow-up period; DX: breast cancer diagnosis